Celgene (NASDAQ: CELG ) became Foundation's second large partner in May 2011. The goal for Celgene was to use Foundation's cancer genomic tests to speed up the recruitment process for target patients and identify those patients most likely to respond to Celgene's experimental drugs. This relationship also seems to be going well, since Celgene-backed Agios Pharmaceuticals also struck a deal just last month for a multi-year partnership.
Foundation went on to line up other significant partners. Johnson & Johnson, Sanofi, and the aforementioned Ariad are just a few companies developing cancer drugs that now rely on Foundation's technology.